Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
3.880
+0.020 (0.52%)
At close: Apr 17, 2026, 4:00 PM EDT
3.853
-0.027 (-0.71%)
After-hours: Apr 17, 2026, 7:41 PM EDT

Oramed Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Aug '12
2-1.342.7-
Revenue Growth (YoY)
---50.42%--
Cost of Revenue
1.99----
Gross Profit
0.01-1.342.7-
Selling, General & Admin
8.726.468.7111.96-1.2
Research & Development
6.386.328.9727.64-1.68
Total Operating Expenses
15.112.7817.6839.6-2.88
Operating Income
-15.09-12.78-15.77-40.62.88
Interest Income
89.45-2.2922.892.93-13.13
Interest Expense
--0.85-2.04-0.2
Other Non-Operating Income (Expense)
0.96----0.18
Total Non-Operating Income (Expense)
90.41-3.1420.862.93-13.11
Pretax Income
75.32-15.925.09-37.663.25
Provision for Income Taxes
11.313.18-0.1-0.09
Net Income
64.05-19.065.53-36.563.34
Minority Interest in Earnings
-0.03-0.04-0.44-1.2-
Net Income to Common
64.05-19.065.53-36.563.34
Net Income Growth
----114.22%
Shares Outstanding (Basic)
414140396
Shares Outstanding (Diluted)
424141396
Shares Change (YoY)
3.84%0.70%4.02%562.71%8.63%
EPS (Basic)
1.53-0.480.14-0.94-0.57
EPS (Diluted)
1.50-0.480.14-0.94-0.57
Shares Outstanding
39.2839.9240.3439.566.67
Free Cash Flow
-9.15-8.43-10.55-28.41-2.3
Free Cash Flow Per Share
-0.22-0.21-0.26-0.73-0.39
Gross Margin
0.65%-100.00%100.00%-
Operating Margin
-754.40%--1176.79%-1501.96%-
Profit Margin
3200.80%-379.70%-1397.11%-
FCF Margin
-457.70%--787.24%-1051.20%-
EBITDA
-14.97-12.59-15.57-40.542.9
EBITDA Margin
-748.35%--1162.16%-1499.82%-
EBIT
-15.09-12.78-15.77-40.62.88
EBIT Margin
-754.40%--1176.79%-1501.96%-
Effective Tax Rate
15.01%-19.99%0.00%-0.27%-2.77%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q